Entelos

About Entelos

Entelos, founded in 1996, operates as a biosimulation technology and services firm geared towards the pharmaceutical, healthcare, nutrition, and consumer product markets. The company's core business revolves around its proprietary PhysioLab platforms, which are predictive, computer-based models of human physiology. These platforms create 'virtual patients' to simulate biological responses to therapies and chemical compounds, thereby aiming to reduce the time, cost, and risks associated with product development.

The company's business model is centered on providing predictive biosimulation software and consulting services to drug discovery and development organizations. Clients, including pharmaceutical and biotechnology companies like Novartis and Johnson & Johnson Pharmaceutical Research & Development, utilize Entelos' technology to support various stages of the R&D process. This includes target selection and validation, biomarker identification, inter-species translation from animal models to human trials, clinical trial design optimization, and patient stratification. The technology allows for the simulation of virtual clinical trials on diverse patient populations by generating numerous virtual patients with varying disease statuses, genetics, and lifestyle factors. This capability has significant applications in the field of personalized medicine.

Historically, Entelos has grown through strategic acquisitions, such as the purchase of toxicology data provider Iconix Biosciences in 2007 to integrate safety and toxicity prediction into its efficacy models. The company faced financial challenges, leading to a delisting from London's AIM in 2009 and a Chapter 11 bankruptcy filing in 2011. Subsequently, in January 2014, the consulting services business of Entelos was acquired by Rosa & Co., a drug development consulting firm. This acquisition expanded Rosa's expertise in quantitative systems pharmacology, particularly in cardiovascular, immunology, and metabolism biology. Post-acquisition, the 'Entelos' identity has been continued by the Entelos Institute, a non-profit research organization. This institute focuses on democratizing access to advanced computational tools and predictive models to address global challenges in areas like drug discovery, materials design, and hazard prediction, aligning with UN Sustainable Development Goals.